Hunter Capital signs transaction agreement for reverse acquisition of ResoTher Pharma
The agreement was announced on October 30, 2026, marking a significant corporate restructuring event for the Danish biotechnology company.
Latest ResoTher Pharma News & Updates
See the latest news and media coverage for ResoTher Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biotech developing resolution therapies for cardiovascular inflammation
resotherpharma.com- Headquarters
- Holte, Denmark
- Founded year
- 2016
- Company type
- Private company
- Number of employees
- 10–19
- Industry
- Biotechnology & Medical Research
Last updated
Latest news about ResoTher Pharma
In short: ResoTher Pharma reported positive Phase 2a results for RTP-026 and advanced its reverse takeover with Hunter Capital.
Company announcements
ResoTher Pharma highlights Phase IIa RTP-026 results
The company plans a December Spotlight Stock Market listing and initiates an international Phase IIb study with over 200 patients for its inflammation-resolving therapy.
ResoTher Pharma reports Phase 2a RTP-026 results
The safety trial showed strong efficacy signals for cardioprotection in severe heart attack patients, discussed with BioStock.
ResoTher Pharma reports safe Phase 2a results for RTP-026
RTP-026 demonstrated strong safety and promising efficacy signals in patients with severe heart attacks.
Media coverage
Danish biotech company plans listing on Spotlight Stock Market
The Danish biotech company Resother Pharma, which develops new drugs to limit harmful inflammation and protect organs from permanent damage, plans a listing on the...
Hunter Capital RTO 1 agrees to reverse takeover of ResoTher Pharma
Hunter Capital RTO 1 has entered into an agreement for the acquisition of the Danish biotechnology company ResoTher Pharma as part of a share capital increase. ResoTher Pharma will be...
ResoTher's RTP-026 shows early efficacy signals in severe heart attack - Biostock
Copenhagen-based ResoTher Pharma is developing a new class of resolution therapeutics designed to activate the body's natural mechanisms for resolving excessive inflammation and provide better...
Hunter Capital RTO1 reports a slight loss in line with expectations: CEO focuses on the process with ResoTher Pharma
The reverse merger company Hunter Capital RTO1, as expected, reported no revenue and a negative result for the second quarter, while work...
Never miss news about ResoTher Pharma
Track ResoTher Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Trending companies
Discover what's making headlines across other trending companies.
SharkNinja
NRx
Ropes & Gray
HighTech Kaunas
inretrn
Poundland
Farrer & Co
Specialfastigheter
SISAB
Hemsö
Stenvalvet
Liljewall
Veidekke
Locum
NCC
Kriminalvården
Archus
Nyréns
Peab
MVB
VGR fastigheter
AIX
ByggDialog
Tengbom
LINK
Dynacon
Delphidata
Waystream
Netnod
Open Infra
PENN Entertainment
BrandCrowd
Itancia
Paul, Weiss
Prime Medicine
AN2 Therapeutics